242 related articles for article (PubMed ID: 24590688)
1. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
4. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
5. Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity.
Casanova-Ferrer F; Gallego JJ; Fiorillo A; Urios A; Ríos MP; León JL; Ballester MP; Escudero-García D; Kosenko E; Belloch V; Montoliu C
J Transl Med; 2024 Jan; 22(1):49. PubMed ID: 38217008
[TBL] [Abstract][Full Text] [Related]
6. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis.
Ahluwalia V; Betrapally NS; Hylemon PB; White MB; Gillevet PM; Unser AB; Fagan A; Daita K; Heuman DM; Zhou H; Sikaroodi M; Bajaj JS
Sci Rep; 2016 May; 6():26800. PubMed ID: 27225869
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
8. Linkage of gut microbiome with cognition in hepatic encephalopathy.
Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cognitivity, proinflammatory cytokines, and brain magnetic resonance imaging in minimal hepatic encephalopathy induced by cirrhosis and extrahepatic portal vein obstruction.
Yadav SK; Goel A; Saraswat VA; Thomas MA; Wang E; Marincola FM; Haris M; Gupta RK
J Gastroenterol Hepatol; 2016 Dec; 31(12):1986-1994. PubMed ID: 27119420
[TBL] [Abstract][Full Text] [Related]
11. Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Goyal O; Sidhu SS; Kishore H
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
Sharma K; Pant S; Misra S; Dwivedi M; Misra A; Narang S; Tewari R; Bhadoria AS
Saudi J Gastroenterol; 2014; 20(4):225-32. PubMed ID: 25038208
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
Bajaj JS; Pinkerton SD; Sanyal AJ; Heuman DM
Hepatology; 2012 Apr; 55(4):1164-71. PubMed ID: 22135042
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
16. Decreased Mean Kurtosis in the Putamen is a Diagnostic Feature of Minimal Hepatic Encephalopathy in Patients with Cirrhosis.
Sato T; Endo K; Kakisaka K; Suzuki Y; Kooka Y; Sawara K; Ito K; Sasaki M; Takikawa Y
Intern Med; 2019 May; 58(9):1217-1224. PubMed ID: 30626839
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.
Ballester MP; Gallego JJ; Fiorillo A; Casanova-Ferrer F; Giménez-Garzó C; Escudero-García D; Tosca J; Ríos MP; Montón C; Durbán L; Ballester J; Benlloch S; Urios A; San-Miguel T; Kosenko E; Serra MÁ; Felipo V; Montoliu C
Sci Rep; 2022 Feb; 12(1):2463. PubMed ID: 35165326
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
Kimer N; Pedersen JS; Tavenier J; Christensen JE; Busk TM; Hobolth L; Krag A; Al-Soud WA; Mortensen MS; Sørensen SJ; Møller S; Bendtsen F;
J Gastroenterol Hepatol; 2018 Jan; 33(1):307-314. PubMed ID: 28671712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
